• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=9598804).
  
• Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
  

PubMed=6976407; DOI=10.1084/jem.154.6.1764
Albino A.P., Lloyd K.O., Houghton A.N., Oettgen H.F., Old L.J.
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient Implications for the study of tumor antigens.
J. Exp. Med. 154:1764-1778(1981)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=7175440; DOI=10.1084/jem.156.6.1755
Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
J. Exp. Med. 156:1755-1766(1982)

PubMed=6864164; DOI=10.1084/jem.158.1.53
Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F., Old L.J.
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983)

PubMed=2886213
Dracopoli N.C., Alhadeff B., Houghton A.N., Old L.J.
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma.
Cancer Res. 47:3995-4000(1987)

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998)